Proprietary AI analyst is now available
- Public Comps
- Prime Medicine
Prime Medicine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Prime Medicine and similar public comparables like enGene, Tectonic Therapeutic, Ironwood Pharmaceuticals, TTY Biopharm and more.
Prime Medicine Overview
About Prime Medicine
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Founded
2019
HQ

Employees
214
Website
Financials (LTM)
EV
$550M
Valuation Multiples
Start free trialPrime Medicine Financials
Prime Medicine reported last 12-month revenue of $8M and negative EBITDA of ($190M).
In the same LTM period, Prime Medicine generated $8M in gross profit, ($190M) in EBITDA losses, and had net loss of ($193M).
Revenue (LTM)
Prime Medicine P&L
In the most recent fiscal year, Prime Medicine reported revenue of $5M and EBITDA of ($195M).
Prime Medicine is unprofitable as of last fiscal year, with EBITDA margin of (4220%) and net margin of (4342%).
Financial data powered by Morningstar, Inc.
Prime Medicine Stock Performance
Prime Medicine has current market cap of $571M, and enterprise value of $550M.
Market Cap Evolution
Prime Medicine's stock price is $3.16.
Prime Medicine share price decreased by 11.0% in the last 30 days, and increased by 31.1% in the last year.
Prime Medicine has an EPS (earnings per share) of $-1.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $550M | $571M | 10.1% | -11.0% | -9.2% | 31.1% | $-1.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPrime Medicine Valuation Multiples
Prime Medicine trades at 65.2x EV/Revenue multiple, and (2.9x) EV/EBITDA.
EV / Revenue (LTM)
Prime Medicine Financial Valuation Multiples
As of June 18, 2026, Prime Medicine has market cap of $571M and EV of $550M.
Prime Medicine has a P/E ratio of (3.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Prime Medicine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Prime Medicine Margins & Growth Rates
Prime Medicine grew revenue by 177% but EBITDA decreased by 6% in the last fiscal year.
In the most recent fiscal year, Prime Medicine reported EBITDA margin of (4220%) and net margin of (4342%).
Prime Medicine Margins
Prime Medicine Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Prime Medicine Operational KPIs
Prime Medicine's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
Prime Medicine's Rule of 40 is (1260%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prime Medicine's Rule of X is (995%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Prime Medicine Competitors
Prime Medicine competitors include enGene, Tectonic Therapeutic, Ironwood Pharmaceuticals, TTY Biopharm, Nxera Pharma, Clarity Pharmaceuticals, CHO Pharma, Boiron, Aquestive Therapeutics and Candel Therapeutics.
Most Prime Medicine public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | |||
| - | - | (4.7x) | - | |||
| 3.2x | 2.6x | 6.9x | 4.4x | |||
| 2.6x | 2.5x | 7.0x | - | |||
| 4.3x | 3.8x | (43.1x) | 88.1x | |||
| - | 2081.3x | - | (5.5x) | |||
| 10893.8x | - | (59.3x) | - | |||
| 0.9x | - | 6.9x | - | |||
This data is available for Pro users. Sign up to see all Prime Medicine competitors and their valuation data. Start Free Trial | ||||||
Prime Medicine VC Funding History
Before going public, Prime Medicine raised $385M in total equity funding, across 4 rounds.
Last private valuation of Prime Medicine was $1B, after raising $200M in July 2021 from ARCH Venture Partners, Arrive, Casdin Capital, and 9 other investors.
Prime Medicine Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Prime Medicine
| When was Prime Medicine founded? | Prime Medicine was founded in 2019. |
| Where is Prime Medicine headquartered? | Prime Medicine is headquartered in United States. |
| How many employees does Prime Medicine have? | As of today, Prime Medicine has over 214 employees. |
| Who is the CEO of Prime Medicine? | Prime Medicine's CEO is Allan Reine. |
| Is Prime Medicine publicly listed? | Yes, Prime Medicine is a public company listed on Nasdaq. |
| What is the stock symbol of Prime Medicine? | Prime Medicine trades under PRME ticker. |
| When did Prime Medicine go public? | Prime Medicine went public in 2022. |
| Who are competitors of Prime Medicine? | Prime Medicine main competitors include enGene, Tectonic Therapeutic, Ironwood Pharmaceuticals, TTY Biopharm, Nxera Pharma, Clarity Pharmaceuticals, CHO Pharma, Boiron, Aquestive Therapeutics, Candel Therapeutics. |
| What is the current market cap of Prime Medicine? | Prime Medicine's current market cap is $571M. |
| What is the current revenue of Prime Medicine? | Prime Medicine's last 12 months revenue is $8M. |
| What is the current revenue growth of Prime Medicine? | Prime Medicine revenue growth (NTM/LTM) is 105%. |
| What is the current EV/Revenue multiple of Prime Medicine? | Current revenue multiple of Prime Medicine is 65.2x. |
| Is Prime Medicine profitable? | No, Prime Medicine is not profitable. |
| What is the current EBITDA of Prime Medicine? | Prime Medicine has negative EBITDA and is not profitable. |
| What is Prime Medicine's EBITDA margin? | Prime Medicine's last 12 months EBITDA margin is (2258%). |
| What is the current EV/EBITDA multiple of Prime Medicine? | Current EBITDA multiple of Prime Medicine is (2.9x). |
| What is the current FCF of Prime Medicine? | Prime Medicine's last 12 months FCF is ($156M). |
| What is Prime Medicine's FCF margin? | Prime Medicine's last 12 months FCF margin is (1850%). |
| What is the current EV/FCF multiple of Prime Medicine? | Current FCF multiple of Prime Medicine is (3.5x). |
| How many companies Prime Medicine has acquired to date? | Prime Medicine hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Prime Medicine has invested to date? | Prime Medicine hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Prime Medicine
Lists including Prime Medicine
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.